ES2262087T3 - Compuestos heteroaromiticos biciclicos como inhibidores de proteina tirosina cinasa. - Google Patents
Compuestos heteroaromiticos biciclicos como inhibidores de proteina tirosina cinasa.Info
- Publication number
- ES2262087T3 ES2262087T3 ES04076761T ES04076761T ES2262087T3 ES 2262087 T3 ES2262087 T3 ES 2262087T3 ES 04076761 T ES04076761 T ES 04076761T ES 04076761 T ES04076761 T ES 04076761T ES 2262087 T3 ES2262087 T3 ES 2262087T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- fluorobenzyloxy
- quinazolinamine
- methanesulfonyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 140
- 239000003112 inhibitor Substances 0.000 title description 3
- 102000004169 proteins and genes Human genes 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 title description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title description 2
- -1 pyridylmethoxy Chemical group 0.000 claims abstract description 128
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 239000012453 solvate Substances 0.000 claims abstract description 32
- 125000005843 halogen group Chemical group 0.000 claims abstract description 28
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 6
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims abstract description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims abstract description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 69
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 25
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 150000001412 amines Chemical class 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 16
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- DNHCEIAFWBGYFK-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(F)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 DNHCEIAFWBGYFK-UHFFFAOYSA-N 0.000 claims description 4
- RRONZTYLARBRBH-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(F)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1 RRONZTYLARBRBH-UHFFFAOYSA-N 0.000 claims description 3
- YAPPGADRBQSUIE-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=1C=C(OCC=2C=C(F)C=CC=2)C(OC)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CSC(CNCCS(C)(=O)=O)=N1 YAPPGADRBQSUIE-UHFFFAOYSA-N 0.000 claims description 3
- CJGPKVRBUPRPTR-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=1C=C(OCC=2C=C(F)C=CC=2)C(OC)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CC=C(CNCCS(C)(=O)=O)O1 CJGPKVRBUPRPTR-UHFFFAOYSA-N 0.000 claims description 3
- QEHYWVNDAWPVRJ-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=CC(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 QEHYWVNDAWPVRJ-UHFFFAOYSA-N 0.000 claims description 3
- RZEMPBRXCDBLDH-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=CC(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 RZEMPBRXCDBLDH-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- HRAXMJGGCFDZBT-UHFFFAOYSA-N 7-fluoro-n-(3-fluoro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C(=CC3=NC=NC(NC=4C=C(F)C(OCC=5C=CC=CC=5)=CC=4)=C3C=2)F)=C1 HRAXMJGGCFDZBT-UHFFFAOYSA-N 0.000 claims description 2
- CMPYWDJZUOBIIO-UHFFFAOYSA-N 7-fluoro-n-(3-fluoro-4-phenylmethoxyphenyl)-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1F)=CC=C1OCC1=CC=CC=C1 CMPYWDJZUOBIIO-UHFFFAOYSA-N 0.000 claims description 2
- GUXDRWBSRNGGPZ-UHFFFAOYSA-N 7-fluoro-n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C(=CC3=NC=NC(NC=4C=C(F)C(OCC=5C=C(F)C=CC=5)=CC=4)=C3C=2)F)=C1 GUXDRWBSRNGGPZ-UHFFFAOYSA-N 0.000 claims description 2
- YOHWLAPRGKJAEL-UHFFFAOYSA-N 7-fluoro-n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1F)=CC=C1OCC1=CC=CC(F)=C1 YOHWLAPRGKJAEL-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 108091005682 Receptor kinases Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- OCBFHZWUJAUMPR-UHFFFAOYSA-N n-(3-bromo-4-phenylmethoxyphenyl)-7-fluoro-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C(=CC3=NC=NC(NC=4C=C(Br)C(OCC=5C=CC=CC=5)=CC=4)=C3C=2)F)=C1 OCBFHZWUJAUMPR-UHFFFAOYSA-N 0.000 claims description 2
- ZADGIWJEHDJLCZ-UHFFFAOYSA-N n-(3-bromo-4-phenylmethoxyphenyl)-7-fluoro-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1Br)=CC=C1OCC1=CC=CC=C1 ZADGIWJEHDJLCZ-UHFFFAOYSA-N 0.000 claims description 2
- IHZCJKWDMHPKAC-UHFFFAOYSA-N n-(3-bromo-4-phenylmethoxyphenyl)-7-methoxy-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3N=C(CNCCS(C)(=O)=O)SC=3)C(OC)=CC2=NC=NC=1NC(C=C1Br)=CC=C1OCC1=CC=CC=C1 IHZCJKWDMHPKAC-UHFFFAOYSA-N 0.000 claims description 2
- NKLDCSQPJCETMA-UHFFFAOYSA-N n-(3-bromo-4-phenylmethoxyphenyl)-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1Br)=CC=C1OCC1=CC=CC=C1 NKLDCSQPJCETMA-UHFFFAOYSA-N 0.000 claims description 2
- WVPMKVVGRCIEBV-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-6-[5-[(2-methylsulfonylethylamino)methyl]furan-3-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1 WVPMKVVGRCIEBV-UHFFFAOYSA-N 0.000 claims description 2
- BOJBCNAHDOIFBE-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-7-fluoro-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C(=CC3=NC=NC(NC=4C=C(Cl)C(OCC=5C=CC=CC=5)=CC=4)=C3C=2)F)=C1 BOJBCNAHDOIFBE-UHFFFAOYSA-N 0.000 claims description 2
- NOJHSHOVOCTOHJ-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-7-fluoro-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 NOJHSHOVOCTOHJ-UHFFFAOYSA-N 0.000 claims description 2
- UTGTXIQFRUQSMS-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-7-methoxy-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3N=C(CNCCS(C)(=O)=O)SC=3)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 UTGTXIQFRUQSMS-UHFFFAOYSA-N 0.000 claims description 2
- INOHEVIDYKGWNH-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 INOHEVIDYKGWNH-UHFFFAOYSA-N 0.000 claims description 2
- SRUGAMVGSFQHCH-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-7-methoxy-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3N=C(CNCCS(C)(=O)=O)SC=3)C(OC)=CC2=NC=NC=1NC(C=C1F)=CC=C1OCC1=CC=CC=C1 SRUGAMVGSFQHCH-UHFFFAOYSA-N 0.000 claims description 2
- GFRIWQBALIBSCZ-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1F)=CC=C1OCC1=CC=CC=C1 GFRIWQBALIBSCZ-UHFFFAOYSA-N 0.000 claims description 2
- FVRXRENVHJBKFO-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoro-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1Br)=CC=C1OCC1=CC=CC(F)=C1 FVRXRENVHJBKFO-UHFFFAOYSA-N 0.000 claims description 2
- SGJFGVYDLIDRBD-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3N=C(CNCCS(C)(=O)=O)SC=3)C(OC)=CC2=NC=NC=1NC(C=C1Br)=CC=C1OCC1=CC=CC(F)=C1 SGJFGVYDLIDRBD-UHFFFAOYSA-N 0.000 claims description 2
- UODLBPXYHJNREK-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1Br)=CC=C1OCC1=CC=CC(F)=C1 UODLBPXYHJNREK-UHFFFAOYSA-N 0.000 claims description 2
- HNCNTMHPAYQWSL-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoro-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C(=CC3=NC=NC(NC=4C=C(Cl)C(OCC=5C=C(F)C=CC=5)=CC=4)=C3C=2)F)=C1 HNCNTMHPAYQWSL-UHFFFAOYSA-N 0.000 claims description 2
- QLHIYBDUQPWZAA-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoro-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 QLHIYBDUQPWZAA-UHFFFAOYSA-N 0.000 claims description 2
- XURMGEAAVZEGOJ-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3N=C(CNCCS(C)(=O)=O)SC=3)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 XURMGEAAVZEGOJ-UHFFFAOYSA-N 0.000 claims description 2
- LNFFTZLZPLIOIX-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 LNFFTZLZPLIOIX-UHFFFAOYSA-N 0.000 claims description 2
- MNHCZHFLNIOWQH-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(F)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 MNHCZHFLNIOWQH-UHFFFAOYSA-N 0.000 claims description 2
- XHNANHFGZRZRAU-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3N=C(CNCCS(C)(=O)=O)SC=3)C(OC)=CC2=NC=NC=1NC(C=C1F)=CC=C1OCC1=CC=CC(F)=C1 XHNANHFGZRZRAU-UHFFFAOYSA-N 0.000 claims description 2
- DXPUMHHTGDHAKK-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1F)=CC=C1OCC1=CC=CC(F)=C1 DXPUMHHTGDHAKK-UHFFFAOYSA-N 0.000 claims description 2
- 150000003557 thiazoles Chemical class 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- MNNXRVSQOABRRP-UHFFFAOYSA-N N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-4-thiazolyl]-4-quinazolinamine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 MNNXRVSQOABRRP-UHFFFAOYSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- VSCPXIGUZBDNSV-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-6-[5-[(2-methylsulfonylethylamino)methyl]furan-3-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC(C=2C=C3C(NC=4C=C(F)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1 VSCPXIGUZBDNSV-UHFFFAOYSA-N 0.000 claims 1
- OKOQGGNYPJNMTO-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Br)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 OKOQGGNYPJNMTO-UHFFFAOYSA-N 0.000 claims 1
- UGLDUUSMNMDDMH-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoro-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C(=CC3=NC=NC(NC=4C=C(Br)C(OCC=5C=C(F)C=CC=5)=CC=4)=C3C=2)F)=C1 UGLDUUSMNMDDMH-UHFFFAOYSA-N 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 47
- 239000000203 mixture Substances 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 43
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- 239000007787 solid Substances 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108060006698 EGF receptor Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- SDNXQWUJWNTDCC-UHFFFAOYSA-N 2-methylsulfonylethanamine Chemical compound CS(=O)(=O)CCN SDNXQWUJWNTDCC-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
- BDAIUOPDSRAOKI-UHFFFAOYSA-N 4-chloro-6-iodoquinazoline Chemical compound C1=C(I)C=C2C(Cl)=NC=NC2=C1 BDAIUOPDSRAOKI-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 5
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 4
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 101150093908 PDGFRB gene Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 3
- AOGRSEYOPSZLKA-UHFFFAOYSA-N 6-chloro-n-[4-[(3-fluorophenyl)methoxy]phenyl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(Cl)=NC=C4N=CN=3)=CC=2)=C1 AOGRSEYOPSZLKA-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 3
- 102000001332 SRC Human genes 0.000 description 3
- 108060006706 SRC Proteins 0.000 description 3
- 125000005219 aminonitrile group Chemical group 0.000 description 3
- 150000001448 anilines Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 125000005879 dioxolanyl group Chemical group 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001012 protector Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003556 thioamides Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- WQFNPHMSIVIAMP-UHFFFAOYSA-N 2-amino-4-fluoro-5-iodobenzoic acid Chemical compound NC1=CC(F)=C(I)C=C1C(O)=O WQFNPHMSIVIAMP-UHFFFAOYSA-N 0.000 description 2
- UROSHBSDTBPGPU-UHFFFAOYSA-N 2-bromo-4-(1,3-dioxolan-2-yl)-1,3-thiazole Chemical compound S1C(Br)=NC(C2OCCO2)=C1 UROSHBSDTBPGPU-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- CKPNVNAKQGYUSK-UHFFFAOYSA-N 4,6-dichloropyrido[3,4-d]pyrimidine Chemical compound N1=CN=C2C=NC(Cl)=CC2=C1Cl CKPNVNAKQGYUSK-UHFFFAOYSA-N 0.000 description 2
- LMKDKHDGVBPEKI-UHFFFAOYSA-N 4-[(3-fluorophenyl)methoxy]aniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC(F)=C1 LMKDKHDGVBPEKI-UHFFFAOYSA-N 0.000 description 2
- OHHIZVCDNOKAMJ-UHFFFAOYSA-N 6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-n-[4-[(3-fluorophenyl)methoxy]phenyl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(=NC=C4N=CN=3)C=3OC(=CC=3)C3OCCO3)=CC=2)=C1 OHHIZVCDNOKAMJ-UHFFFAOYSA-N 0.000 description 2
- QXBDUGGENUWAME-UHFFFAOYSA-N 7-fluoro-6-iodo-1h-quinazolin-4-one Chemical compound FC1=C(I)C=C2C(O)=NC=NC2=C1 QXBDUGGENUWAME-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 2
- 101100503636 Danio rerio fyna gene Proteins 0.000 description 2
- 101150018272 FYN gene Proteins 0.000 description 2
- 206010061968 Gastric neoplasm Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 101150028321 Lck gene Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229950003476 aminothiazole Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- QAWTYRYXDYHQNU-UHFFFAOYSA-N diazathiane Chemical compound NSN QAWTYRYXDYHQNU-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 2
- RPJDOKPJFVVEHP-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]furan-3-yl]quinazolin-4-amine Chemical compound O1C=CC(C=2C=C3C(NC=4C=C(F)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1CNCCS(=O)(=O)C RPJDOKPJFVVEHP-UHFFFAOYSA-N 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000003566 phosphorylation assay Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000026267 regulation of growth Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- PFXVKGGZWQQTSE-UHFFFAOYSA-N sulfuryl dicyanide Chemical compound N#CS(=O)(=O)C#N PFXVKGGZWQQTSE-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HJKXIUOEIPMBPT-UHFFFAOYSA-N 1,3-thiazol-2-amine;2,2,2-trifluoroacetamide Chemical compound NC1=NC=CS1.NC(=O)C(F)(F)F HJKXIUOEIPMBPT-UHFFFAOYSA-N 0.000 description 1
- ZGTFNNUASMWGTM-UHFFFAOYSA-N 1,3-thiazole-2-carbaldehyde Chemical compound O=CC1=NC=CS1 ZGTFNNUASMWGTM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MNQVIZWWCRPZOK-UHFFFAOYSA-N 2-bromo-1,3-thiazole-4-carbaldehyde Chemical compound BrC1=NC(C=O)=CS1 MNQVIZWWCRPZOK-UHFFFAOYSA-N 0.000 description 1
- CYWGSFFHHMQKET-UHFFFAOYSA-N 2-methylsulfanylethanamine Chemical compound CSCCN CYWGSFFHHMQKET-UHFFFAOYSA-N 0.000 description 1
- QGKGASXQTBQINX-UHFFFAOYSA-N 3,4-dihydro-1h-pyrimidin-2-one Chemical compound O=C1NCC=CN1 QGKGASXQTBQINX-UHFFFAOYSA-N 0.000 description 1
- WCWJQZJGFZHWHB-UHFFFAOYSA-N 3-[4-[3-bromo-N-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound FC=1C=C(CON(C=2C3=C(N=CN=2)C=NC(=C3)C2=C(OC=C2)C=O)C2=CC(=CC=C2)Br)C=CC=1 WCWJQZJGFZHWHB-UHFFFAOYSA-N 0.000 description 1
- VEERQQATNKZLEO-UHFFFAOYSA-N 3-[4-[3-fluoro-N-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound FC=1C=C(CON(C=2C3=C(N=CN=2)C=NC(=C3)C2=C(OC=C2)C=O)C2=CC(=CC=C2)F)C=CC=1 VEERQQATNKZLEO-UHFFFAOYSA-N 0.000 description 1
- XFGRSRQUIAXQNB-UHFFFAOYSA-N 3-chloro-4-[(2-fluorophenyl)methoxy]aniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC=C1F XFGRSRQUIAXQNB-UHFFFAOYSA-N 0.000 description 1
- AYPFEYDGZDPAPE-UHFFFAOYSA-N 3-chloro-4-[(3-fluorophenyl)methoxy]aniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC(F)=C1 AYPFEYDGZDPAPE-UHFFFAOYSA-N 0.000 description 1
- VQCZIZIHGIJMII-UHFFFAOYSA-N 3-chloro-4-[(4-fluorophenyl)methoxy]aniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=C(F)C=C1 VQCZIZIHGIJMII-UHFFFAOYSA-N 0.000 description 1
- DKTRZBWXGOPYIX-UHFFFAOYSA-N 3-chloro-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(Cl)=C1 DKTRZBWXGOPYIX-UHFFFAOYSA-N 0.000 description 1
- WOWKZTBVWKKGJV-UHFFFAOYSA-N 3-chloro-4-phenylmethoxyaniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC=C1 WOWKZTBVWKKGJV-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- XLEYXHRMSUPJST-UHFFFAOYSA-N 3-fluoro-4-phenylmethoxyaniline Chemical compound FC1=CC(N)=CC=C1OCC1=CC=CC=C1 XLEYXHRMSUPJST-UHFFFAOYSA-N 0.000 description 1
- AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 1
- FVUMUZSSIVMHEQ-UHFFFAOYSA-N 4-(1-benzylindazol-5-yl)-6-iodo-1h-quinazolin-4-amine Chemical compound N1C=NC2=CC=C(I)C=C2C1(N)C(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 FVUMUZSSIVMHEQ-UHFFFAOYSA-N 0.000 description 1
- HCKJWAIVDILSFO-UHFFFAOYSA-N 4-chloro-7-fluoro-6-iodoquinazoline;hydrochloride Chemical compound Cl.C1=NC(Cl)=C2C=C(I)C(F)=CC2=N1 HCKJWAIVDILSFO-UHFFFAOYSA-N 0.000 description 1
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
- DBPKMSBWOKAKLA-UHFFFAOYSA-N 4-chloropyrimidine Chemical group ClC1=CC=NC=N1 DBPKMSBWOKAKLA-UHFFFAOYSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- SMDGIJITNLOLSD-UHFFFAOYSA-N 5-[2-(3-bromo-4-phenylmethoxyanilino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(Br)=CC=1NC(N=C1C=N2)=NC=C1C=C2C1=CC=C(C=O)O1 SMDGIJITNLOLSD-UHFFFAOYSA-N 0.000 description 1
- FGBNTBAYARRIFX-UHFFFAOYSA-N 5-[2-(3-chloro-4-phenylmethoxyanilino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(Cl)=CC=1NC(N=C1C=N2)=NC=C1C=C2C1=CC=C(C=O)O1 FGBNTBAYARRIFX-UHFFFAOYSA-N 0.000 description 1
- RJWSSMCAIODRAG-UHFFFAOYSA-N 5-[2-(3-fluoro-4-phenylmethoxyanilino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(F)=CC=1NC(N=C1C=N2)=NC=C1C=C2C1=CC=C(C=O)O1 RJWSSMCAIODRAG-UHFFFAOYSA-N 0.000 description 1
- YNPIJTZJPIIXEI-UHFFFAOYSA-N 5-[2-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3N=C4C=NC(=CC4=CN=3)C=3OC(C=O)=CC=3)=CC=2)Cl)=C1 YNPIJTZJPIIXEI-UHFFFAOYSA-N 0.000 description 1
- RHVSMDWUYUYCCE-UHFFFAOYSA-N 5-[4-(3-bromo-4-phenylmethoxyphenyl)-7-fluoroquinazolin-6-yl]furan-2-carbaldehyde Chemical compound C=12C=C(C=3OC(C=O)=CC=3)C(F)=CC2=NC=NC=1C(C=C1Br)=CC=C1OCC1=CC=CC=C1 RHVSMDWUYUYCCE-UHFFFAOYSA-N 0.000 description 1
- SPYDUPKZAXEXRA-UHFFFAOYSA-N 5-[4-(3-chloro-4-phenylmethoxyanilino)-7-fluoroquinazolin-6-yl]furan-2-carbaldehyde Chemical compound C=12C=C(C=3OC(C=O)=CC=3)C(F)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 SPYDUPKZAXEXRA-UHFFFAOYSA-N 0.000 description 1
- FSQQOQJTZOTQMX-UHFFFAOYSA-N 5-[4-(3-chloro-4-phenylmethoxyanilino)quinazolin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(Cl)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CC=C(C=O)O1 FSQQOQJTZOTQMX-UHFFFAOYSA-N 0.000 description 1
- NPKSKAFUBBUMDT-UHFFFAOYSA-N 5-[4-(3-fluoro-4-phenylmethoxyanilino)quinazolin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(F)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CC=C(C=O)O1 NPKSKAFUBBUMDT-UHFFFAOYSA-N 0.000 description 1
- LRRYDADCSUDXKL-UHFFFAOYSA-N 5-[4-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoroquinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(=CC=2)C=2C3=CC(=C(F)C=C3N=CN=2)C=2OC(C=O)=CC=2)Br)=C1 LRRYDADCSUDXKL-UHFFFAOYSA-N 0.000 description 1
- XQPZOUAAXRXPAM-UHFFFAOYSA-N 5-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(=CC=C4N=CN=3)C=3OC(C=O)=CC=3)=CC=2)Cl)=C1 XQPZOUAAXRXPAM-UHFFFAOYSA-N 0.000 description 1
- DEECATMLEICPKT-UHFFFAOYSA-N 5-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoroquinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(=CC=2)C=2C3=CC(=C(F)C=C3N=CN=2)C=2OC(C=O)=CC=2)Cl)=C1 DEECATMLEICPKT-UHFFFAOYSA-N 0.000 description 1
- ASQPKYWSIJSYSQ-UHFFFAOYSA-N 5-[4-[3-fluoro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(=CC=C4N=CN=3)C=3OC(C=O)=CC=3)=CC=2)F)=C1 ASQPKYWSIJSYSQ-UHFFFAOYSA-N 0.000 description 1
- PGQXNMBXXLJOMX-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]-3-methoxyanilino]quinazolin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=C(F)C=CC=2)C(OC)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CC=C(C=O)O1 PGQXNMBXXLJOMX-UHFFFAOYSA-N 0.000 description 1
- LTCHCGGNDRFIMA-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(=NC=C4N=CN=3)C=3OC(C=O)=CC=3)=CC=2)=C1 LTCHCGGNDRFIMA-UHFFFAOYSA-N 0.000 description 1
- XYTSDPWYAUQDNM-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]furan-3-carbaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(=NC=C4N=CN=3)C=3OC=C(C=O)C=3)=CC=2)=C1 XYTSDPWYAUQDNM-UHFFFAOYSA-N 0.000 description 1
- DXNXDDHUDHVDEO-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(=CC=C4N=CN=3)C=3OC(C=O)=CC=3)=CC=2)=C1 DXNXDDHUDHVDEO-UHFFFAOYSA-N 0.000 description 1
- GVZIVDUUBRKFLP-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]phenyl]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(=CC=2)C=2C3=CC(=NC=C3N=CN=2)C=2OC(C=O)=CC=2)=C1 GVZIVDUUBRKFLP-UHFFFAOYSA-N 0.000 description 1
- GFFPERKNLBNMQB-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]phenyl]pyrido[3,4-d]pyrimidin-6-yl]furan-3-carbaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(=CC=2)C=2C3=CC(=NC=C3N=CN=2)C=2OC=C(C=O)C=2)=C1 GFFPERKNLBNMQB-UHFFFAOYSA-N 0.000 description 1
- JFJNDMNYNYLFLJ-UHFFFAOYSA-N 6-bromo-4-chloroquinazoline Chemical compound C1=C(Br)C=C2C(Cl)=NC=NC2=C1 JFJNDMNYNYLFLJ-UHFFFAOYSA-N 0.000 description 1
- BBPUOYYUBFLNML-UHFFFAOYSA-N 6-chloro-1h-pyrido[3,4-d]pyrimidin-4-one Chemical compound N1=CNC(=O)C2=C1C=NC(Cl)=C2 BBPUOYYUBFLNML-UHFFFAOYSA-N 0.000 description 1
- BQZAKZHHKHKXOR-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(3-fluoro-4-phenylmethoxyphenyl)quinazolin-4-amine Chemical compound FC1=CC(NC=2C3=CC(Cl)=C(F)C=C3N=CN=2)=CC=C1OCC1=CC=CC=C1 BQZAKZHHKHKXOR-UHFFFAOYSA-N 0.000 description 1
- WELMWKSCIDCGPR-UHFFFAOYSA-N 6-chloro-n-(3-chloro-4-phenylmethoxyphenyl)-7-fluoroquinazolin-4-amine Chemical compound C=12C=C(Cl)C(F)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 WELMWKSCIDCGPR-UHFFFAOYSA-N 0.000 description 1
- RSHUMBXTLYMGNO-UHFFFAOYSA-N 6-chloro-n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(Cl)=C(F)C=C4N=CN=3)=CC=2)Cl)=C1 RSHUMBXTLYMGNO-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- LPZWLHBWBRJJEH-UHFFFAOYSA-N COC1=C(C=CC(=C1)NC2=NC=NC3=CC=CC=C32)OCC4=CC(=CC=C4)F Chemical compound COC1=C(C=CC(=C1)NC2=NC=NC3=CC=CC=C32)OCC4=CC(=CC=C4)F LPZWLHBWBRJJEH-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- RFMQOHXWHFHOJF-UHFFFAOYSA-N cyano thiocyanate Chemical compound N#CSC#N RFMQOHXWHFHOJF-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- BADWIIDKTXQYLW-UHFFFAOYSA-N ethenylstannane Chemical compound [SnH3]C=C BADWIIDKTXQYLW-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005283 haloketone group Chemical group 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- URMBEUCXPXFDFN-UHFFFAOYSA-N n-(3-bromo-4-phenylmethoxyphenyl)-6-chloro-7-fluoroquinazolin-4-amine Chemical compound C=12C=C(Cl)C(F)=CC2=NC=NC=1NC(C=C1Br)=CC=C1OCC1=CC=CC=C1 URMBEUCXPXFDFN-UHFFFAOYSA-N 0.000 description 1
- AXVKGZLOECWENV-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1 AXVKGZLOECWENV-UHFFFAOYSA-N 0.000 description 1
- CGNGHWDSBASZIG-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]furan-3-yl]quinazolin-4-amine Chemical compound O1C=CC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1CNCCS(=O)(=O)C CGNGHWDSBASZIG-UHFFFAOYSA-N 0.000 description 1
- LPCDFUQIFYVPHL-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-6-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(Cl)=C(F)C=C4N=CN=3)=CC=2)Br)=C1 LPCDFUQIFYVPHL-UHFFFAOYSA-N 0.000 description 1
- XYOWEAWGISJQKC-UHFFFAOYSA-N n-[4-(benzenesulfonyl)phenyl]-7-methoxyquinazolin-4-amine Chemical compound N=1C=NC2=CC(OC)=CC=C2C=1NC(C=C1)=CC=C1S(=O)(=O)C1=CC=CC=C1 XYOWEAWGISJQKC-UHFFFAOYSA-N 0.000 description 1
- PXLFTAHKQCDJNC-UHFFFAOYSA-N n-[6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-7-methoxyquinazolin-4-yl]-n-phenylbenzenesulfonamide Chemical compound C=12C=C(C=3OC(=CC=3)C3OCCO3)C(OC)=CC2=NC=NC=1N(S(=O)(=O)C=1C=CC=CC=1)C1=CC=CC=C1 PXLFTAHKQCDJNC-UHFFFAOYSA-N 0.000 description 1
- JLVLBDODYLEYOY-UHFFFAOYSA-N n-phenylpyrimidin-4-amine Chemical compound C=1C=NC=NC=1NC1=CC=CC=C1 JLVLBDODYLEYOY-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- 150000008518 pyridopyrimidines Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DVFXLNFDWATPMW-IWOKLKJTSA-N tert-butyldiphenylsilyl Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DVFXLNFDWATPMW-IWOKLKJTSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9800569.7A GB9800569D0 (en) | 1998-01-12 | 1998-01-12 | Heterocyclic compounds |
| GB9800569 | 1998-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2262087T3 true ES2262087T3 (es) | 2006-11-16 |
Family
ID=10825153
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04076762T Expired - Lifetime ES2319119T3 (es) | 1998-01-12 | 1999-01-08 | Derivados de quinazolina y piridopirimidina. |
| ES04076761T Expired - Lifetime ES2262087T3 (es) | 1998-01-12 | 1999-01-08 | Compuestos heteroaromiticos biciclicos como inhibidores de proteina tirosina cinasa. |
| ES99902522T Expired - Lifetime ES2221354T3 (es) | 1998-01-12 | 1999-01-08 | Compuestos biciclicos heteroaromaticos como inhibidores de la proteina tirosina quinasa. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04076762T Expired - Lifetime ES2319119T3 (es) | 1998-01-12 | 1999-01-08 | Derivados de quinazolina y piridopirimidina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99902522T Expired - Lifetime ES2221354T3 (es) | 1998-01-12 | 1999-01-08 | Compuestos biciclicos heteroaromaticos como inhibidores de la proteina tirosina quinasa. |
Country Status (47)
Families Citing this family (443)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE368665T1 (de) | 1997-08-22 | 2007-08-15 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| DK1119567T3 (da) | 1998-10-08 | 2005-07-25 | Astrazeneca Ab | Quinazolinderivater |
| GB2345486A (en) * | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| DK1553097T3 (da) | 1999-02-10 | 2010-12-13 | Astrazeneca Ab | Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil |
| GB9910579D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| GB9910580D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| CA2375259C (en) | 1999-06-21 | 2009-04-28 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| JP2003504363A (ja) | 1999-07-09 | 2003-02-04 | グラクソ グループ リミテッド | プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類 |
| CN1391562A (zh) * | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 用作药物的喹唑啉衍生物 |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| JP2003520855A (ja) * | 2000-01-28 | 2003-07-08 | アストラゼネカ アクチボラグ | 化学的化合物 |
| GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| AR035851A1 (es) * | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
| WO2001083432A2 (en) | 2000-05-02 | 2001-11-08 | Array Biopharma, Inc. | Process for the reduction of cyano-substituted sulfones to aminoalkylene-substituted sulfones |
| MXPA02012870A (es) | 2000-06-22 | 2003-05-14 | Pfizer Prod Inc | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. |
| EE200200715A (et) | 2000-06-28 | 2004-08-16 | Astrazeneca Ab | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena |
| EP1792902A1 (en) * | 2000-06-30 | 2007-06-06 | Glaxo Group Limited | Processes for preparation of 5-(6-quinazolinyl)-furan-2-carbaldehydes |
| IL153111A0 (en) * | 2000-06-30 | 2003-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| JP2004505964A (ja) | 2000-08-09 | 2004-02-26 | アストラゼネカ アクチボラグ | Ｖｅｇｆ阻害活性を有するキノリン誘導体 |
| US7547702B2 (en) | 2000-09-20 | 2009-06-16 | Ortho-Mcneil Pharmaceutical, Inc. | 4-amino-quinazolines |
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| US7253184B2 (en) | 2000-11-02 | 2007-08-07 | Astrazeneca Ab | 4-Substituted quinolines as antitumor agents |
| WO2002044166A1 (en) | 2000-11-02 | 2002-06-06 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| EP2796468A2 (en) | 2001-01-05 | 2014-10-29 | Pfizer Inc | Antibodies to insulin-like growth factor I receptor |
| EP1512413A3 (en) * | 2001-01-16 | 2009-09-23 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer |
| DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| EP1377281A4 (en) * | 2001-03-15 | 2009-06-17 | Rhode Island Hospital | Taurine compounds |
| TWI261055B (en) * | 2001-03-23 | 2006-09-01 | Bayer Corp | Rho-Kinase Inhibitors |
| PE20020958A1 (es) * | 2001-03-23 | 2002-11-14 | Bayer Corp | Inhibidores de la rho-quinasa |
| ATE330956T1 (de) | 2001-04-13 | 2006-07-15 | Pfizer Prod Inc | Bizyklisch substituierte 4- aminopyridopyrimidinderivate |
| WO2002092578A1 (en) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| US6995171B2 (en) | 2001-06-21 | 2006-02-07 | Agouron Pharmaceuticals, Inc. | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents |
| US20090197852A9 (en) * | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
| US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CA2472619A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Corporation | Fused pyrimidine derivates as rho-kinase inhibitors |
| RS63204A (sr) | 2002-01-17 | 2006-10-27 | Neurogen Corporation | Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina |
| MXPA04007196A (es) | 2002-01-23 | 2005-06-08 | Bayer Pharmaceuticals Corp | Inhibidores de rho-quinasa. |
| MXPA04007191A (es) | 2002-01-23 | 2005-03-31 | Bayer Pharmaceuticals Corp | Derivados de pirimidina como inhibidores de rho-quinasa. |
| DK1474420T3 (da) | 2002-02-01 | 2012-05-21 | Astrazeneca Ab | Quinazolinforbindelser |
| JP4389205B2 (ja) * | 2002-02-06 | 2009-12-24 | 宇部興産株式会社 | ４−アミノキナゾリン化合物の製法 |
| US20050176740A1 (en) * | 2002-04-08 | 2005-08-11 | Spector Neil L. | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
| DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| AU2003241898A1 (en) * | 2002-06-03 | 2003-12-19 | Mitsubishi Pharma Corporation | PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR |
| UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| US20040048887A1 (en) * | 2002-07-09 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| US7504408B2 (en) | 2002-07-09 | 2009-03-17 | Astrazeneca Ab | Quinzoline derivatives for use in the treatment of cancer |
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
| GB0225579D0 (en) * | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| US8505468B2 (en) * | 2002-11-19 | 2013-08-13 | Sharp Kabushiki Kaisha | Substrate accommodating tray |
| AR042461A1 (es) * | 2002-12-13 | 2005-06-22 | Neurogen Corp | Analogos 2-sustituidos de quinazolin-4-il - amina. composiciones farmaceuticas |
| PL377713A1 (pl) | 2002-12-19 | 2006-02-06 | Pfizer Inc. | Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu |
| AU2003292435A1 (en) * | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
| JPWO2004060400A1 (ja) * | 2003-01-06 | 2006-05-11 | 那波 宏之 | 上皮成長因子受容体を分子標的とする抗精神病薬 |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
| MXPA05012939A (es) | 2003-05-30 | 2006-05-17 | Astrazeneca Uk Ltd | Procedimiento. |
| TW200510373A (en) | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
| US7329664B2 (en) | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
| MXPA06000508A (es) | 2003-07-18 | 2006-04-05 | Amgen Inc | Agentes de union especifica al factor del crecimiento de los hepatocitos. |
| WO2005011607A2 (en) | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| EP1660504B1 (en) | 2003-08-29 | 2008-10-29 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
| GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| EP1682123A1 (en) * | 2003-11-07 | 2006-07-26 | SmithKline Beecham (Cork) Limited | Cancer treatment method |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| EP1697384B1 (en) * | 2003-12-18 | 2008-04-02 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents |
| GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| JP2007532658A (ja) * | 2004-04-16 | 2007-11-15 | スミスクライン ビーチャム コーポレーション | がんの治療方法 |
| NZ550796A (en) | 2004-05-06 | 2010-07-30 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
| EP1768963A4 (en) * | 2004-06-03 | 2009-06-10 | Smithkline Beecham Cork Ltd | CANCER TREATMENT METHOD |
| US7452887B2 (en) * | 2004-06-04 | 2008-11-18 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| WO2005120512A2 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| US20100226931A1 (en) * | 2004-06-24 | 2010-09-09 | Nicholas Valiante | Compounds for immunopotentiation |
| WO2006002422A2 (en) * | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
| WO2006008639A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| BRPI0513915A (pt) | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
| JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
| JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
| WO2006064196A1 (en) | 2004-12-14 | 2006-06-22 | Astrazeneca Ab | Pyrazolopyrimidine compounds as antitumor agents |
| WO2006066267A2 (en) * | 2004-12-17 | 2006-06-22 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| WO2006068826A2 (en) * | 2004-12-21 | 2006-06-29 | Smithkline Beecham Corporation | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
| US7812022B2 (en) * | 2004-12-21 | 2010-10-12 | Glaxosmithkline Llc | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| CN101103028A (zh) * | 2005-01-14 | 2008-01-09 | 神经能质公司 | 经杂芳基取代的喹啉-4-基氨类似物 |
| NZ595313A (en) | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| EP3300739A3 (en) | 2005-03-31 | 2018-07-18 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
| CA2606207C (en) * | 2005-04-19 | 2014-11-18 | Smithkline Beecham (Cork) Limited | Pharmaceutical composition |
| KR101203328B1 (ko) | 2005-04-26 | 2012-11-20 | 화이자 인코포레이티드 | Ｐ-카드헤린 항체 |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| HN2006031275A (es) | 2005-09-07 | 2010-10-29 | Amgen Fremont Inc | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
| US7820683B2 (en) | 2005-09-20 | 2010-10-26 | Astrazeneca Ab | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer |
| EP1926996B1 (en) | 2005-09-20 | 2011-11-09 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| JP5688877B2 (ja) | 2005-11-11 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌疾患の治療用キナゾリン誘導体 |
| US7807673B2 (en) * | 2005-12-05 | 2010-10-05 | Glaxosmithkline Llc | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| ES2329419T3 (es) * | 2006-01-31 | 2009-11-25 | F. Hoffmann-La Roche Ag | 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas. |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| US20090203718A1 (en) * | 2006-04-13 | 2009-08-13 | Smithkline Beecham (Cork) Ltd. | Cancer treatment method |
| EP2010521A1 (en) | 2006-04-19 | 2009-01-07 | Novartis Ag | Indazole compounds and methods for inhibition of cdc7 |
| EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| ES2318616T3 (es) * | 2006-06-01 | 2009-05-01 | Cellzome Ag | Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70. |
| JP5399900B2 (ja) | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｉｇｆｂｐ２インヒビター |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US20110053964A1 (en) * | 2006-08-22 | 2011-03-03 | Roger Tung | 4-aminoquinazoline derivatives and methods of use thereof |
| EP2054063A4 (en) * | 2006-08-22 | 2010-10-27 | Concert Pharmaceuticals Inc | 4-AMINOCHINAZOLINE DERIVATIVES AND METHOD FOR THEIR USE |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| DK2068880T3 (da) | 2006-09-18 | 2012-07-23 | Boehringer Ingelheim Int | Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer |
| JP2010505811A (ja) * | 2006-10-04 | 2010-02-25 | ファイザー・プロダクツ・インク | カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体 |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| WO2008054633A1 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | Hydrazone derivatives as kinase inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| CN102123712B (zh) | 2006-12-13 | 2014-03-19 | 默沙东公司 | 使用igf1r抑制剂治疗癌症的方法 |
| EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| ES2449482T3 (es) | 2007-01-09 | 2014-03-19 | Amgen Inc. | Derivados de bis-aril-amida útiles para el tratamiento de cáncer |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| CN101245050A (zh) | 2007-02-14 | 2008-08-20 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的盐 |
| CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| ES2529790T3 (es) | 2007-04-13 | 2015-02-25 | Dana-Farber Cancer Institute, Inc. | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB |
| AU2008249745B2 (en) * | 2007-05-09 | 2012-01-12 | Pfizer Inc. | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
| WO2008154469A1 (en) * | 2007-06-11 | 2008-12-18 | Smithkline Beecham (Cork) Limited | Quinazoline salt compounds |
| UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| MX2010001918A (es) | 2007-08-21 | 2010-03-11 | Amgen Inc | Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino. |
| ES2424745T3 (es) | 2007-09-07 | 2013-10-08 | Agensys, Inc. | Anticuerpos y moléculas relacionadas que se unen a las proteínas 24P4C12 |
| US20090215802A1 (en) * | 2007-09-13 | 2009-08-27 | Protia, Llc | Deuterium-enriched lapatinib |
| JP2011500723A (ja) * | 2007-10-19 | 2011-01-06 | ファルマ・マール・ソシエダード・アノニマ | 改善された抗腫瘍治療 |
| WO2009055343A2 (en) | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| KR20100087185A (ko) | 2007-10-29 | 2010-08-03 | 낫코 파마 리미티드 | 항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체 |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| BRPI0820722A2 (pt) | 2007-12-20 | 2015-06-16 | Novartis Ag | Derivados de tiazol usados como inibidores de pi 3 cinases |
| CN101492445A (zh) * | 2008-01-22 | 2009-07-29 | 孙飘扬 | 杂芳族化合物、其制备方法以及其用途 |
| AU2009209541A1 (en) * | 2008-01-30 | 2009-08-06 | Pharma Mar, S.A. | Improved antitumoral treatments |
| JP2011513370A (ja) * | 2008-03-07 | 2011-04-28 | ファルマ・マール・ソシエダード・アノニマ | 改善された抗腫瘍治療法 |
| HUE035184T2 (en) | 2008-03-18 | 2018-05-02 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| US8252805B2 (en) | 2008-05-07 | 2012-08-28 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
| WO2009140144A1 (en) * | 2008-05-15 | 2009-11-19 | Teva Pharmaceutical Industries Ltd. | Forms of crystalline lapatinib and processes for preparation thereof |
| CN101584696A (zh) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| US20100197915A1 (en) * | 2008-08-06 | 2010-08-05 | Leonid Metsger | Lapatinib intermediates |
| EP2158913A1 (en) | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| EP2158912A1 (en) | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| WO2010027848A2 (en) * | 2008-08-26 | 2010-03-11 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib compounds and processes for the preparation thereof |
| WO2010045495A2 (en) | 2008-10-16 | 2010-04-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
| EP2358666A1 (en) | 2008-11-03 | 2011-08-24 | Natco Pharma Limited | A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts |
| MX2011004824A (es) | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Uso de derivados de butano catecólico en terapia contra el cáncer. |
| RS52754B2 (sr) | 2009-01-16 | 2022-08-31 | Exelixis Inc | Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma |
| CN101787017A (zh) * | 2009-01-23 | 2010-07-28 | 岑均达 | 光学纯喹唑啉类化合物 |
| CA2748943A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
| EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法 |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8481503B2 (en) | 2009-03-06 | 2013-07-09 | Merck Sharp & Dohme Corp. | Combination cancer therapy with an AKT inhibitor and other anticancer agents |
| EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| US8816077B2 (en) | 2009-04-17 | 2014-08-26 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
| WO2010120386A1 (en) | 2009-04-17 | 2010-10-21 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| HUE044629T2 (hu) | 2009-07-06 | 2019-11-28 | Boehringer Ingelheim Int | Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| SI2467140T1 (sl) | 2009-08-21 | 2016-10-28 | Novartis Ag | Lapatinib za zdravljenje raka |
| JP2013503846A (ja) | 2009-09-01 | 2013-02-04 | ファイザー・インク | ベンズイミダゾール誘導体 |
| US8916574B2 (en) | 2009-09-28 | 2014-12-23 | Qilu Pharmaceutical Co., Ltd. | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| WO2011039759A1 (en) * | 2009-09-29 | 2011-04-07 | Natco Pharma Limited | A new process for the preparation of lapatinib and its pharmaceutically acceptable salts |
| JP2013510564A (ja) | 2009-11-13 | 2013-03-28 | パンガエア ビオテック、ソシエダッド、リミターダ | 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー |
| CN102079759B (zh) * | 2009-12-01 | 2014-09-17 | 天津药物研究院 | 6位取代的喹唑啉类衍生物、其制备方法和用途 |
| WO2011069074A2 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| RS55487B2 (sr) | 2010-02-12 | 2024-06-28 | Pfizer | Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
| WO2011101644A1 (en) | 2010-02-18 | 2011-08-25 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Triazolo [4, 5 - b] pyridin derivatives |
| AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2519826A2 (en) | 2010-03-03 | 2012-11-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| CA2793742C (en) | 2010-03-23 | 2015-06-23 | Scinopharm Taiwan Ltd. | Process and intermediates for preparing lapatinib |
| US8710221B2 (en) | 2010-03-23 | 2014-04-29 | Scinopharm Taiwan, Ltd. | Process and intermediates for preparing lapatinib |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| WO2011121317A1 (en) | 2010-04-01 | 2011-10-06 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors |
| JP2013526578A (ja) | 2010-05-21 | 2013-06-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
| US9180129B2 (en) | 2010-05-21 | 2015-11-10 | Novartis Ag | Combination of lapatinib and trametinib |
| JP6257324B2 (ja) | 2010-06-04 | 2018-01-10 | アブラクシス バイオサイエンス， エルエルシー | 膵臓がんの処置方法 |
| JP2013538042A (ja) | 2010-06-16 | 2013-10-10 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | エンドプラスミンに対する抗体およびその使用 |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| JP2013539962A (ja) | 2010-07-09 | 2013-10-31 | ジェネンテック， インコーポレイテッド | 抗ニューロピリン抗体及び使用方法 |
| CN102344444B (zh) * | 2010-07-23 | 2015-07-01 | 岑均达 | 光学纯喹唑啉类化合物 |
| CN102344445B (zh) * | 2010-07-23 | 2015-11-25 | 岑均达 | 光学纯喹唑啉类化合物 |
| AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| CA2808236A1 (en) | 2010-08-31 | 2012-03-08 | Genentech, Inc. | Biomarkers and methods of treatment |
| WO2012052948A1 (en) | 2010-10-20 | 2012-04-26 | Pfizer Inc. | Pyridine- 2- derivatives as smoothened receptor modulators |
| WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
| JP2014501725A (ja) | 2010-11-24 | 2014-01-23 | グラクソ グループ リミテッド | Ｈｇｆを標的とする多特異的抗原結合タンパク質 |
| CN102558159A (zh) * | 2010-12-20 | 2012-07-11 | 天津药物研究院 | 4-取代间甲磺酰胺苯胺基-喹唑啉衍生物及其制备方法和用途 |
| CN102558160B (zh) * | 2010-12-20 | 2015-09-23 | 天津药物研究院 | 4-取代对甲磺酰胺苯胺基-喹唑啉衍生物及其制备方法和用途 |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| EP2655364A4 (en) | 2010-12-23 | 2014-06-11 | Apotex Pharmachem Inc | PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS DITOSYLATE SALT |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| MX343706B (es) | 2011-01-31 | 2016-11-18 | Novartis Ag | Derivados heterocíclicos novedosos. |
| WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| KR101940340B1 (ko) | 2011-03-04 | 2019-01-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 아미노-퀴놀린 |
| AU2012225693A1 (en) | 2011-03-04 | 2013-09-19 | Newgen Therapeutics, Inc. | Alkyne substituted quinazoline compound and methods of use |
| CA2829219C (en) | 2011-03-09 | 2021-03-16 | Richard G. Pestell | Prostate cancer cell lines, gene signatures and uses thereof |
| EP2685980B1 (en) | 2011-03-17 | 2017-12-06 | The Trustees Of The University Of Pennsylvania | Methods and use of bifunctional enzyme-building clamp-shaped molecules |
| WO2012125904A1 (en) | 2011-03-17 | 2012-09-20 | The Trustees Of The University Of Pennsylvania | Mutation mimicking compounds that bind to the kinase domain of egfr |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| PT2688887E (pt) | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
| CN103841975A (zh) | 2011-04-01 | 2014-06-04 | 基因泰克公司 | Akt抑制剂化合物和厄洛替尼的组合以及使用方法 |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| WO2012155339A1 (zh) | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| KR101953210B1 (ko) | 2011-05-19 | 2019-02-28 | 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ | 단백질 키나아제 억제제로서의 대환식 화합물 |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| ITMI20110894A1 (it) | 2011-05-20 | 2012-11-21 | Italiana Sint Spa | Impurezza del lapatinib e suoi sali |
| JP5414739B2 (ja) | 2011-05-25 | 2014-02-12 | 三菱電機株式会社 | 半導体テスト治具 |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
| WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
| PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
| US9499530B2 (en) * | 2011-08-01 | 2016-11-22 | Hangzhou Minsheng Institutes For Pharma Research | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament |
| WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| WO2013033380A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
| MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
| US20130084287A1 (en) | 2011-09-30 | 2013-04-04 | Genentech, Inc. | Diagnostic markers |
| AU2011378675B2 (en) | 2011-10-04 | 2017-10-05 | Epsilogen Ltd | IgE anti -HMW-MAA antibody |
| BR112014009890A2 (pt) | 2011-10-28 | 2020-10-27 | Novartis Ag | derivados de purina e seu uso no tratamento de doença |
| RU2014114015A (ru) | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | Способы лечения воспалительных расстройств с использованием антител против m-csf |
| WO2013080218A1 (en) | 2011-11-28 | 2013-06-06 | Fresenius Kabi Oncology Ltd. | Novel intermediates and process for the preparation of lapatinib and its pharmaceutically acceptable salts |
| KR20140117644A (ko) | 2012-01-31 | 2014-10-07 | 스미스클라인 비이참 (코르크) 리미티드 | 암을 치료하는 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US9453836B2 (en) | 2012-05-14 | 2016-09-27 | Richard G. Pestell | Use of modulators of CCR5 in the treatment of cancer and cancer metastasis |
| BR112014028420A2 (pt) | 2012-05-16 | 2017-09-19 | Novartis Ag | regime de dosagem para um inibidor de quinase pi-3 |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| WO2014062838A2 (en) | 2012-10-16 | 2014-04-24 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
| CZ2012712A3 (cs) | 2012-10-17 | 2014-04-30 | Zentiva, K.S. | Nový způsob výroby klíčového intermediátu výroby lapatinibu |
| CN102942561A (zh) * | 2012-11-06 | 2013-02-27 | 深圳海王药业有限公司 | 4-氨基喹唑啉杂环化合物及其用途 |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| RU2015115397A (ru) | 2012-12-21 | 2017-01-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аморфная форма производного хинолина и способ его получения |
| CN103896889B (zh) * | 2012-12-27 | 2016-05-25 | 上海创诺制药有限公司 | 拉帕替尼中间体及其制备方法和应用 |
| HK1217092A1 (zh) | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| EP2958552B1 (en) | 2013-02-19 | 2017-06-21 | Hexal AG | Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof |
| BR112015020139A2 (pt) | 2013-02-20 | 2017-07-18 | Kala Pharmaceuticals Inc | compostos terapêuticos e usos dos mesmos |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| BR112015019624A2 (pt) | 2013-02-21 | 2017-07-18 | Glaxosmithkline Ip Dev Ltd | quinazolinas como inibidores de quinase |
| EP2958592A1 (en) | 2013-02-22 | 2015-12-30 | F. Hoffmann-La Roche AG | Methods of treating cancer and preventing drug resistance |
| CN103159747A (zh) * | 2013-02-26 | 2013-06-19 | 常州鸿创高分子科技有限公司 | 一种二对甲苯磺酸拉帕替尼的合成方法 |
| US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| RU2015137610A (ru) | 2013-03-06 | 2017-04-10 | Дженентек, Инк. | Способы лечения и профилактики лекарственной резистентности злокачественных опухолей |
| RU2693480C2 (ru) | 2013-03-14 | 2019-07-03 | Толеро Фармасьютикалз, Инк. | Ингибиторы jak2 и alk2 и способы их использования |
| HK1220916A1 (zh) | 2013-03-14 | 2017-05-19 | 基因泰克公司 | 治疗癌症和预防癌症药物抗性的方法 |
| CN105339001A (zh) | 2013-03-15 | 2016-02-17 | 基因泰克公司 | 治疗癌症和预防癌症耐药性的方法 |
| WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| WO2014170910A1 (en) | 2013-04-04 | 2014-10-23 | Natco Pharma Limited | Process for the preparation of lapatinib |
| US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
| HU231012B1 (hu) | 2013-05-24 | 2019-11-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Lapatinib sók |
| CN105705494B (zh) * | 2013-07-18 | 2017-12-15 | 锦州奥鸿药业有限责任公司 | 喹唑啉衍生物及其药物组合物，以及作为药物的用途 |
| CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
| CN105764511B (zh) | 2013-10-04 | 2019-01-11 | 艾普托斯生物科学公司 | 用于治疗癌症的组合物和方法 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| CN103554091B (zh) * | 2013-11-05 | 2016-05-18 | 沈阳工业大学 | 喹唑啉衍生物及其制备方法和用途 |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| PL3076969T3 (pl) | 2013-12-06 | 2022-01-17 | Novartis Ag | Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| HRP20191283T1 (hr) | 2014-01-24 | 2019-10-18 | Turning Point Therapeutics, Inc. | Diaril makrocikli kao modulatori protein kinaze |
| EP3111222A1 (en) | 2014-02-26 | 2017-01-04 | Glaxosmithkline Intellectual Property (No. 2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
| WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| EP2937346A1 (en) | 2014-04-24 | 2015-10-28 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Co-crystals of lapatinib |
| WO2015166373A1 (en) | 2014-04-30 | 2015-11-05 | Pfizer Inc. | Cycloalkyl-linked diheterocycle derivatives |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| ES2848857T3 (es) | 2014-07-31 | 2021-08-12 | Us Gov Health & Human Services | Anticuerpos monoclonales humanos contra EphA4 y su uso |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| US20170252335A1 (en) | 2014-10-17 | 2017-09-07 | Novartis Ag | Combination of Ceritinib with an EGFR Inhibitor |
| WO2016100347A2 (en) * | 2014-12-15 | 2016-06-23 | The Regents Of The University Of Michigan | Small molecule inhibitors of egfr and pi3k |
| JP6621477B2 (ja) | 2014-12-18 | 2019-12-18 | ファイザー・インク | ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用 |
| EP3237638B1 (en) | 2014-12-24 | 2020-01-15 | F.Hoffmann-La Roche Ag | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| CN105801565B (zh) * | 2014-12-30 | 2020-04-03 | 天津法莫西医药科技有限公司 | N-[3-氯-4-[(3-氟苯基)甲氧基]苯基]-6-[(5-甲酰基)呋喃-2-基]-4-喹唑啉胺制备方法 |
| AU2016205311B2 (en) | 2015-01-08 | 2022-02-17 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| AU2016214923A1 (en) * | 2015-02-03 | 2017-08-24 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as EGFR inhibitors useful for treating cancers |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| BR112017022666A8 (pt) | 2015-04-20 | 2022-10-18 | Tolero Pharmaceuticals Inc | Preparando resposta à alvocidib por perfilamento mitocondrial |
| CN107709344B (zh) | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | 用于治疗黄病毒科病毒和癌症的核苷类似物 |
| CN111349118B (zh) | 2015-05-18 | 2023-08-22 | 住友制药肿瘤公司 | 具有增加的生物利用度的阿伏西地前药 |
| CN106279307B (zh) * | 2015-05-19 | 2019-07-26 | 正大天晴药业集团股份有限公司 | 芳氨代葡萄糖衍生物、其制备方法及抗肿瘤用途 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| JP6914860B2 (ja) | 2015-07-01 | 2021-08-04 | カリフォルニア インスティチュート オブ テクノロジー | カチオン性粘液酸ポリマー系デリバリーシステム |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| EP4397665A3 (en) | 2015-07-06 | 2024-08-21 | Turning Point Therapeutics, Inc. | Diaryl macrocycle polymorph |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| DK3325488T3 (da) | 2015-07-21 | 2020-09-14 | Turning Point Therapeutics Inc | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer |
| RU2759963C2 (ru) | 2015-08-03 | 2021-11-19 | Сумитомо Даиниппон Фарма Онколоджи, Инк. | Комбинированные терапии для лечения рака |
| US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US11124483B2 (en) | 2015-09-02 | 2021-09-21 | The Regents Of The University Of California | HER3 ligands and uses thereof |
| CN106632276B (zh) * | 2015-10-28 | 2021-06-15 | 上海天慈生物谷生物工程有限公司 | 一种治疗乳腺癌药物的制备方法 |
| MX2018005298A (es) | 2015-11-02 | 2018-06-22 | Novartis Ag | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. |
| EP4015537A1 (en) | 2015-12-01 | 2022-06-22 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| JP6877429B2 (ja) | 2015-12-03 | 2021-05-26 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤 |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| TW201815799A (zh) | 2016-07-28 | 2018-05-01 | 美商Ｔｐ生物醫藥公司 | 巨環激酶抑制劑 |
| US11649289B2 (en) | 2016-08-04 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Anti-ICOS and anti-PD-1 antibody combination therapy |
| CA3036336A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JP6619519B2 (ja) | 2016-12-19 | 2019-12-11 | トレロ ファーマシューティカルズ， インコーポレイテッド | プロファイリングペプチドおよび感受性プロファイリングのための方法 |
| NZ754994A (en) | 2016-12-22 | 2022-12-23 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| BR112020001695A2 (pt) | 2017-07-28 | 2020-07-21 | Turning Point Therapeutics, Inc. | compostos macrocíclicos e usos dos mesmos |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| WO2019075367A1 (en) | 2017-10-13 | 2019-04-18 | Tolero Pharmaceuticals, Inc. | PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER |
| EP3727387A4 (en) | 2017-12-18 | 2021-12-15 | Sterngreene, Inc. | PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS |
| CN111511746B (zh) | 2017-12-19 | 2024-01-09 | 特普医药公司 | 用于治疗疾病的巨环化合物 |
| MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EP3790886B1 (en) | 2018-05-10 | 2024-06-26 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| EP3802535B1 (en) | 2018-06-01 | 2022-12-14 | Amgen, Inc | Kras g12c inhibitors and methods of using the same |
| CA3099799A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| MA51848A (fr) | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| EP3806887A4 (en) | 2018-06-13 | 2022-04-06 | California Institute of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
| BR112020026641A2 (pt) * | 2018-06-27 | 2021-03-30 | Oscotec Inc. | Derivados de piridopirimidinona para o uso como inibidores de axl |
| CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| AU2019352741A1 (en) | 2018-10-04 | 2021-05-06 | Assistance Publique-Hôpitaux De Paris (Aphp) | EGFR inhibitors for treating keratodermas |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| MA54550A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| EA202191730A1 (ru) | 2018-12-20 | 2021-08-24 | Эмджен Инк. | Ингибиторы kif18a |
| JP7659269B2 (ja) * | 2018-12-21 | 2025-04-09 | ユニバーシティ・オブ・ノートル・ダム・デュ・ラック | 抗酸菌症治療のためのｂｄオキシダーゼ阻害剤の発見 |
| WO2020160375A1 (en) | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof |
| NZ778055A (en) | 2019-02-12 | 2025-11-28 | Sumitomo Pharma America Inc | Formulations comprising heterocyclic protein kinase inhibitors |
| CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
| KR20210146287A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置 |
| WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
| MA56397A (fr) | 2019-06-26 | 2022-05-04 | Glaxosmithkline Ip Dev Ltd | Protéines de liaison à l'il1rap |
| JP7640521B2 (ja) | 2019-08-02 | 2025-03-05 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| ES3051918T3 (en) | 2019-08-02 | 2025-12-30 | Amgen Inc | Kif18a inhibitors |
| WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CN114391012B (zh) | 2019-08-02 | 2025-10-31 | 美国安进公司 | 作为kif18a抑制剂的吡啶衍生物 |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| EP4048671B1 (en) | 2019-10-24 | 2026-03-18 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| JP7823816B2 (ja) | 2019-11-04 | 2026-03-04 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｒａｓ阻害剤 |
| KR20220109407A (ko) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| EP4054719B1 (en) | 2019-11-04 | 2026-02-11 | Revolution Medicines, Inc. | Ras inhibitors |
| BR112022008858A2 (pt) | 2019-11-08 | 2022-09-06 | Revolution Medicines Inc | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer |
| WO2021097207A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| JP2023501528A (ja) | 2019-11-14 | 2023-01-18 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成 |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN114929279A (zh) | 2020-01-07 | 2022-08-19 | 锐新医药公司 | Shp2抑制剂给药和治疗癌症的方法 |
| US20230067202A1 (en) | 2020-01-28 | 2023-03-02 | Glaxosmithkline Intellectual Property Development Limited | Combination Treatments and Uses and Methods Thereof |
| WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
| EP4114530A4 (en) * | 2020-03-02 | 2024-04-17 | Turning Point Therapeutics, Inc. | THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS |
| CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
| IL303965A (en) | 2020-12-22 | 2023-08-01 | Mekanistic Therapeutics Llc | Transmuted heteroaryl aminobenzyl compounds as EGFR and/or PI3K inhibitors |
| CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
| US12037346B2 (en) | 2021-04-13 | 2024-07-16 | Nuvalent, Inc. | Amino-substituted heteroaryls for treating cancers with EGFR mutations |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| JP2025500878A (ja) | 2021-12-17 | 2025-01-15 | ジェンザイム・コーポレーション | Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| IL314883A (en) | 2022-03-07 | 2024-10-01 | Amgen Inc | A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| PE20251879A1 (es) | 2022-10-14 | 2025-07-22 | Black Diamond Therapeutics Inc | Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| PE20260039A1 (es) | 2023-04-07 | 2026-01-09 | Revolution Medicines Inc | Inhibidores macrociclicos de ras |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| TW202542151A (zh) | 2023-12-22 | 2025-11-01 | 美商銳格醫藥有限公司 | Ｓｏｓ１抑制劑及其用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4074057A (en) | 1973-12-12 | 1978-02-14 | Takeda Chemical Co., Ltd. | 2-Halopropionic acid and its derivatives |
| US4166735A (en) | 1977-01-21 | 1979-09-04 | Shell Oil Company | Cycloalkanecarboxanilide derivative herbicides |
| EP0222839A4 (en) | 1985-05-17 | 1988-11-09 | Univ Australian | ANTI-MALARIA COMPOUNDS. |
| US5141941A (en) | 1988-11-21 | 1992-08-25 | Ube Industries, Ltd. | Aralkylamine derivatives, and fungicides containing the same |
| US5034393A (en) | 1989-07-27 | 1991-07-23 | Dowelanco | Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives |
| BR9101256A (pt) | 1990-03-30 | 1991-11-05 | Dowelanco | Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| DE4131924A1 (de) | 1991-09-25 | 1993-07-08 | Hoechst Ag | Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
| GB9127252D0 (en) | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| WO1993018035A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| US5326766A (en) | 1992-08-19 | 1994-07-05 | Dreikorn Barry A | 4-(2-(4-(2-pyridinyloxy)phenyl)ethoxy)quinazoline and analogues thereof |
| DE4308014A1 (de) | 1993-03-13 | 1994-09-15 | Hoechst Schering Agrevo Gmbh | Kondensierte Stickstoffheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| GB9312891D0 (en) | 1993-06-22 | 1993-08-04 | Boots Co Plc | Therapeutic agents |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (enExample) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| CA2223081C (en) | 1995-06-07 | 2001-03-06 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| HUP9801177A3 (en) | 1995-11-14 | 1998-11-30 | Pharmacia & Upjohn Spa | Tetrahydronaphthyl, indanyl and indolyl substituted pyrido[2,3-d]pyrimidine and purine derivatives, process for their preparation and pharmaceutical compositions containing them |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| JP4386967B2 (ja) * | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
| HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| ES2191187T3 (es) | 1996-07-13 | 2003-09-01 | Glaxo Group Ltd | Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| MXPA02012870A (es) * | 2000-06-22 | 2003-05-14 | Pfizer Prod Inc | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. |
| IL153111A0 (en) * | 2000-06-30 | 2003-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| DK1474420T3 (da) * | 2002-02-01 | 2012-05-21 | Astrazeneca Ab | Quinazolinforbindelser |
| US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
-
1998
- 1998-01-12 GB GBGB9800569.7A patent/GB9800569D0/en not_active Ceased
- 1998-01-12 RS YUP-448/00A patent/RS49779B/sr unknown
-
1999
- 1999-01-08 MA MA25422A patent/MA26596A1/fr unknown
- 1999-01-08 PT PT04076761T patent/PT1460072E/pt unknown
- 1999-01-08 UA UA2000074012A patent/UA66827C2/uk unknown
- 1999-01-08 NZ NZ505456A patent/NZ505456A/xx not_active IP Right Cessation
- 1999-01-08 CA CA002317589A patent/CA2317589C/en not_active Expired - Lifetime
- 1999-01-08 TR TR2000/02015T patent/TR200002015T2/xx unknown
- 1999-01-08 SI SI9930902T patent/SI1460072T1/sl unknown
- 1999-01-08 AT AT04076761T patent/ATE322491T1/de active
- 1999-01-08 AP APAP/P/2000/001861A patent/AP1446A/en active
- 1999-01-08 SK SK1050-2000A patent/SK285405B6/sk not_active IP Right Cessation
- 1999-01-08 HR HR20000469A patent/HRP20000469B1/xx not_active IP Right Cessation
- 1999-01-08 EA EA200000637A patent/EA002455B1/ru not_active IP Right Cessation
- 1999-01-08 WO PCT/EP1999/000048 patent/WO1999035146A1/en not_active Ceased
- 1999-01-08 AT AT04076762T patent/ATE417847T1/de active
- 1999-01-08 AT AT99902522T patent/ATE270670T1/de active
- 1999-01-08 ME MEP-2000-448A patent/ME00757B/me unknown
- 1999-01-08 DE DE69918528T patent/DE69918528T2/de not_active Expired - Lifetime
- 1999-01-08 ES ES04076762T patent/ES2319119T3/es not_active Expired - Lifetime
- 1999-01-08 CO CO99001037A patent/CO4820390A1/es unknown
- 1999-01-08 US US09/582,746 patent/US6727256B1/en not_active Expired - Lifetime
- 1999-01-08 CN CNB998038873A patent/CN1134438C/zh not_active Expired - Lifetime
- 1999-01-08 JP JP2000527545A patent/JP3390741B2/ja not_active Expired - Lifetime
- 1999-01-08 ES ES04076761T patent/ES2262087T3/es not_active Expired - Lifetime
- 1999-01-08 AU AU22783/99A patent/AU749549C/en not_active Revoked
- 1999-01-08 PT PT99902522T patent/PT1047694E/pt unknown
- 1999-01-08 DE DE69930773T patent/DE69930773T2/de not_active Expired - Lifetime
- 1999-01-08 PT PT04076762T patent/PT1454907E/pt unknown
- 1999-01-08 DE DE122008000048C patent/DE122008000048I1/de active Pending
- 1999-01-08 BR BRPI9906904-0A patent/BR9906904B1/pt not_active IP Right Cessation
- 1999-01-08 DE DE69940128T patent/DE69940128D1/de not_active Expired - Lifetime
- 1999-01-08 EP EP04076761A patent/EP1460072B1/en not_active Expired - Lifetime
- 1999-01-08 IL IL13704199A patent/IL137041A0/xx not_active IP Right Cessation
- 1999-01-08 EP EP04076762A patent/EP1454907B1/en not_active Expired - Lifetime
- 1999-01-08 DK DK04076762T patent/DK1454907T3/da active
- 1999-01-08 DK DK04076761T patent/DK1460072T3/da active
- 1999-01-08 PL PL341595A patent/PL192746B1/pl unknown
- 1999-01-08 EE EEP200000411A patent/EE04616B1/xx active Protection Beyond IP Right Term
- 1999-01-08 ES ES99902522T patent/ES2221354T3/es not_active Expired - Lifetime
- 1999-01-08 KR KR1020007007635A patent/KR100569776B1/ko not_active Expired - Lifetime
- 1999-01-08 SI SI9931027T patent/SI1454907T1/sl unknown
- 1999-01-08 EP EP99902522A patent/EP1047694B1/en not_active Expired - Lifetime
- 1999-01-08 CZ CZ20002587A patent/CZ298047B6/cs not_active IP Right Cessation
- 1999-01-08 GE GEAP19995454A patent/GEP20022678B/en unknown
- 1999-01-08 HU HU0100941A patent/HU227593B1/hu active Protection Beyond IP Right Term
- 1999-01-08 DK DK99902522T patent/DK1047694T3/da active
- 1999-01-08 SI SI9930663T patent/SI1047694T1/xx unknown
- 1999-01-11 ZA ZA9900172A patent/ZA99172B/xx unknown
- 1999-01-11 AR ARP990100083A patent/AR015507A1/es active IP Right Grant
- 1999-01-11 PE PE1999000020A patent/PE20000230A1/es not_active IP Right Cessation
- 1999-01-11 EG EG2699A patent/EG24743A/xx active
- 1999-01-11 MY MYPI99000090A patent/MY124055A/en unknown
- 1999-01-12 TW TW088100388A patent/TW477788B/zh active
-
2000
- 2000-06-27 IS IS5549A patent/IS2276B/is unknown
- 2000-06-27 IL IL137041A patent/IL137041A/en active Protection Beyond IP Right Term
- 2000-07-07 OA OA1200000202A patent/OA11444A/en unknown
- 2000-07-11 NO NO20003561A patent/NO316176B1/no not_active IP Right Cessation
- 2000-08-07 BG BG104668A patent/BG64825B1/bg unknown
-
2002
- 2002-02-08 US US10/071,358 patent/US6713485B2/en not_active Expired - Lifetime
- 2002-03-28 JP JP2002092102A patent/JP2002326990A/ja active Pending
-
2003
- 2003-01-15 US US10/342,810 patent/US20030176451A1/en not_active Abandoned
-
2005
- 2005-02-03 US US11/050,033 patent/US7109333B2/en not_active Expired - Lifetime
-
2006
- 2006-06-19 CY CY20061100812T patent/CY1105618T1/el unknown
- 2006-09-19 US US11/532,926 patent/US20070015775A1/en not_active Abandoned
- 2006-11-10 HR HR20060387A patent/HRP20060387A2/xx not_active Application Discontinuation
-
2007
- 2007-05-23 US US11/752,582 patent/US20070238875A1/en not_active Abandoned
-
2008
- 2008-06-12 AR ARP080102516A patent/AR066982A2/es unknown
- 2008-09-10 LU LU91475C patent/LU91475I2/fr unknown
- 2008-09-12 NL NL300360C patent/NL300360I2/nl unknown
- 2008-09-18 CY CY200800015C patent/CY2008015I1/el unknown
- 2008-10-01 FR FR08C0038C patent/FR08C0038I2/fr active Active
- 2008-11-13 NO NO2008017C patent/NO2008017I1/no not_active IP Right Cessation
-
2009
- 2009-03-06 CY CY20091100253T patent/CY1108859T1/el unknown
-
2010
- 2010-01-22 US US12/691,784 patent/US8513262B2/en not_active Expired - Fee Related
- 2010-12-17 AU AU2010276460A patent/AU2010276460A1/en active Pending
-
2013
- 2013-07-16 US US13/943,049 patent/US8912205B2/en not_active Expired - Fee Related
-
2014
- 2014-11-10 US US14/536,896 patent/US9199973B2/en not_active Expired - Fee Related
-
2015
- 2015-10-20 US US14/887,434 patent/US20160051551A1/en not_active Abandoned
-
2016
- 2016-08-03 US US15/226,949 patent/US20160339027A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2262087T3 (es) | Compuestos heteroaromiticos biciclicos como inhibidores de proteina tirosina cinasa. | |
| ES2206729T3 (es) | Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosina quinasa. | |
| US6169091B1 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| ES2339862T3 (es) | Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos. | |
| CZ8799A3 (cs) | Bicyklické heteroaromatické sloučeniny, způsob jejich výroby a farmaceutický prostředek | |
| US7312330B2 (en) | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | |
| EP0843671A1 (en) | Heterocyclic compounds and pharmaceutical compositions containing them | |
| JPH10505600A (ja) | 置換複素環式化合物および薬剤におけるそれらの使用 | |
| WO1999035132A1 (en) | Heterocyclic compounds | |
| JP2005516023A (ja) | プロテインチロシンキナーゼ阻害剤としてのチエノピリミジン化合物 | |
| IL98542A (en) | Benzoquinazoline derivatives their preparation and pharmaceutical compositions containing them | |
| EP3760633B1 (en) | Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof | |
| JP2009514899A (ja) | チエノピリジンＢ−Ｒａｆキナーゼ阻害剤 | |
| HK1031883B (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| MXPA00006824A (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| HK40042713B (en) | Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof | |
| HK40042713A (en) | Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof |